Glaukos Corporation (GKOS) Year-over-year earnings per share growth for the last twelve months

Official company branding of Glaukos Corp. (GKOS)

In-house implant production combined with partial outsourcing of testing ensures consistent quality, as evidenced by the quarterly EPS fluctuations on GURU.Markets, where 111.10 reflects the latest metric value. Glaukos Corporation (GKOS) CEO Thomas Burns has successfully protected revenues from reductions in insurance payouts, and the current strategy is based on the global scaling of innovative ophthalmological devices for the treatment of glaucoma.

Glaukos (GKOS) - Net earnings per share growth for the trailing year from 07/04/2022 to 11/17/2026

GKOS (Glaukos): analytical breakdowns and indicator data

- share price and expert price forecast:
Initial company analysis:Glaukos Corporation
Flagship merchandise of glaukos.com

The implementation of innovative stents and pharmaceuticals by Glaukos Corporation (GKOS) is transforming global ophthalmic surgery standards. This metric measures the percentage change in net income per share compared to the same quarter last year. This quarterly EPS trend reflects the efficiency with which the company monetizes its technological superiority. The growth of this metric confirms the business's ability to convert medical innovations into actual revenue. A steady increase in this value strengthens the investment attractiveness of the capital.

Competitor analysis

Alcon Corp (ALC) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Bausch Health (BLCO)|Year-over-year earnings per share growth for the last twelve months apellis.com|Belite Bio (BLTE) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Ocular Pharma (OCUL)|HROW (Harrow) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth VRDN (Viridian Corp)|LENZ Corp (LENZ) - Earnings per share growth in annualized terms for the last twelve months|OCS: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months eyepointpharma.com|KOD: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Aldeyra Therapeutics (ALDX)|Year-over-year net earnings per share growth for the last 12 months KALA|IRD - Net earnings per share growth for the trailing year|Year-over-year earnings per share growth for the last twelve months okyopharma.com (OKYO)|Quarterly EPS earnings growth Adverum Biotechnologies Inc. (ADVM)|Year-over-year earnings per share growth for the last twelve months outlooktherapeutics.com OTLK|Year-over-year net earnings per share change for the last twelve months Clearside Biomedical, Inc. (CLSD)|NBY - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months KPRX (kiorapharma.com)|Alimera Sciences (ALIM) - Year-over-year earnings per share growth for the last twelve months|Eyenovia Inc. - Year-over-year earnings per one share growth for the last 12 months|GHSI (Guardion Health Sciences) - Quarterly EPS earnings growth|Ocuphire Pharma - Year-over-year net earnings per share trend for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OPT (Opthea)